

IGF-I (ng/ml) serum concentrations following repeated injections of GRF's analogs (hGRF(1-29) NH₂)

TABLE 1

Treatment (BID, 20 µg/kg SC)	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6
Saline						
(hexanoyl) ₆ hGRF(1-29)NH ₂	216 ± 33	241 ± 33	251 ± 31	262 ± 43	264 ± 31	244 ± 37
	227 ± 16	253 ± 22	306 ± 30 ^a	322 ± 28 ^a	334 ± 29 ^{a,b}	309 ± 29 ^a
(hexenoyl trans-2) ₆ hGRF(1-29)NH ₂	197 ± 20	225 ± 16	271 ± 16 ^a	319 ± 22 ^{a,b}	325 ± 29 ^{a,b}	294 ± 21 ^{a,b}
(hexenoyl trans-3) ₆ hGRF(1-29)NH ₂	222 ± 22	299 ± 30 ^a	357 ± 43 ^a	373 ± 36 ^{a,b}	341 ± 22 ^a	370 ± 38 ^{a,b}

a = P < 0.05 when compared to day 1

b = P < 0.05 when compared to day 2

Day 1 = Pretreatment

Treatment P=0.18

Days P<0.0001

Treatment x Days P < 0.0001

TABLE 2

Treatment (BID, 20 µg/kg, SC)	Day 1 Pretreatment ng/ml	Day 2 ng/ml	Day 3 ng/ml	Day 4 ng/ml	Day 5 ng/ml
hGRF(1-29)NH ₂	252 ± 28	235 ± 19	263 ± 16	258 ± 17	262 ± 24
(Octanoyl) ₆ hGRF(1-29)NH ₂	316 ± 22	287 ± 20	301 ± 37	301 ± 37	318 ± 39
(Hexanoyl) ₆ hGRF(1-29)NH ₂	248 ± 20	281 ± 28	299 ± 26	319 ± 22 ^a	342 ± 21 ^{a,b}
(Butyryl) ₆ hGRF(1-29)NH ₂	278 ± 20	281 ± 24	302 ± 26	289 ± 26	293 ± 23

Treatment P= 0.42

Day P = 0.0004

Treatment x Day P= 0.011

a = P < 0.05 when compared to day 1

b = P < 0.05 when compared to day2

Blood samples for IGF-1 measurements were collected daily prior to first injection of compounds. Data are shown as mean ± SEM of 6 to 7 values per group

November 1994